We use cookies to improve your experience on our site and to show you personalised advertising. To find out more, read our privacy policy and cookie policy

Skip to Content
University of Wollongong Australia. Logo. University of Wollongong Australia. Logo. University of Wollongong Australia. Logo.
  • Search
  • Give
  • Library
  • Current Students
  • Staff
  • UOW Global
    • Our global presence
    • UOW in Dubai
    • UOW in Hong Kong
    • UOW in Malaysia
  • Menu
  • Study at UOW

    • Courses
    • Apply
    • Scholarships & grants
    • Accommodation
    • High-school students
    • Non-school leavers
    • Postgraduate students
    • International students
    • Moving to Wollongong
    • Study abroad & exchange
    • Global sport programs
    • Campuses
    Study at UOW
  • Engage

    • Future student
    • Alumni
    • Visit UOW
    • Woolyungah Indigenous Centre
    • Volunteer
    • The Stand Magazine
    • Community Members
    • Grants and funding
    • Give to UOW
    • Visit the Library
    • Key contacts
    • Educators & school teachers
    Engage with us
  • About UOW

    • Welcome
    • Our people
    • Services
    • Contacts
    • What's on
    • Global presence
    • Media Centre
    • Faculties & schools
    • Our vision & strategy
    • Our Aboriginal & Torres Strait Islander Strategy
    • Our reputation & experience
    • Locations, campuses & partners
    See more about UOW
  • Research

    • Our research
    • Researcher support
    • Research impact
    • Partnership & collaboration
    • Graduate Research School
    • Commercial research
    • Global Challenges
    • Media, news & events
    • Find an expert
    • Our people
    See more about research
  • Industry

    • Generator Lab
    • Advantage SME
    • Success stories
    • Industry research engagement
    • Equipment & Labs
    • Funding opportunities
    • Intellectual property
    • Collaboration for business
    • Collaboration for researchers
    See more about Industry
  • Alumni

    • Benefits
    • Outlook Magazine
    • Events & webinars
    • Volunteer
    • Awards
    • Honorary alumni
    • Testamurs & transcripts
    • Update your details
    • Your career journey
    • Contact us & FAQ
    See more about alumni
  • Quick links

    • Contact directory
    • Staff Intranet
    • Campus maps
    • Transport & parking
    • Key dates
    • Events
    • Password management
    • Jobs
    • Accommodation
    • Policy directory
  • Library
You are here More Pages
  • Home
  • About UOW
  • Media Centre
  • 2022
  • New cancer drug formulations to be tested in Wollongong labs

Media Quick Links

  • Contact UOW Media
  • Visiting campus
  • Image library
  • UOW key facts
  • Find an expert
  • News Corp subscription
  • Sign up for the latest news from UOW Media

April 1, 2022


  • Story By
  • Emily O'Keefe, IHMRI
  • Photo By
  • Paul Jones
Share
Type
General News
Category
Health and Medicine
Tags
InnovationResearchSDG 3: Good Health and Wellbeing

UOW in the News

New cancer drug formulations to be tested in Wollongong labs

UOW and IHMRI researchers look to improve delivery methods of anti-cancer drug Zantrene®


Researchers from the University of Wollongong (UOW) and the Illawarra Health and Medical Research Institute (IHMRI) will soon be undertaking pre-clinical evaluation of new Zantrene® formulations designed by Race Oncology as part of a new research collaboration.  

The program will be led by Professor Marie Ranson from UOW’s Molecular Horizons in partnership with Race Oncology’s Principal Scientist, Professor Michael Kelso, a former UOW academic and IHMRI affiliated researcher.

Professor Ranson is an esteemed cancer biologist based at IHMRI, with extensive experience in drug development and formulation.    

“This is an exciting and valuable collaboration for Race as we develop new Zantrene® formulations and expand our pipeline. We are very much looking forward to working with Professor Ranson on this important program,” says Race Oncology’s Chief Scientific Officer, Dr Daniel Tillett.

Race Oncology is developing new Zantrene® formulations that offer the potential for long-acting peripheral (IV) administration in an outpatient setting. Current administration of Zantrene® requires the use of a central venous catheter in a hospital setting. While this is standard practice for the delivery of many chemotherapy drugs, longer-acting and more patient-friendly routes of administration are desirable.

The collaboration also aims to advance development of formulation approaches that could allow Zantrene® to be delivered orally.

“Zantrene® shows immense promise as an effective new cancer drug, the opportunity to work with Race to develop new drug formulations that could translate into tangible benefits for cancer patients is extremely exciting,” says Professor Ranson.

About Race Oncology

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that Zantrene® protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines to improve their ability to target breast cancer. Race is evaluating this discovery.

The Company also has compelling clinical data for Zantrene® as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene®.

Learn more at www.raceoncology.com 

Media Contacts for this article

UOW Media Office

You may also be interested in

How Catie’s great-grandfather paved the way for her to achieve her dreams
Top health leadership award for UOW academic
UOW researcher awarded $1 million NHMRC funding to focus on deadly Strep A bacteria
Services & Help
  • Current students
  • Library
  • Information technology
  • Accommodation
  • Security & safety
  • Pool, gym & retail
News, Media & Events
  • Media Centre
  • The Stand
  • Alumni Magazine
  • Research news
  • Events
  • Find an expert
Faculties
  • Arts, Social Sciences & Humanities
  • Business & Law
  • Engineering & Information Sciences
  • Science, Medicine & Health
Administration
  • Graduation
  • Environment
  • Policy directory
  • Learning and teaching
  • Financial Services
  • Access to information
  • Jobs
UOW Entities
  • Innovation Campus
  • UOW College Australia
  • UOW College Hong Kong
  • UOW in Dubai
  • UOW Global Enterprises
  • UOW Malaysia KDU
  • UOW Pulse
Connect with us
  • Facebook
  • Twitter
  • YouTube
  • Instagram
  • LinkedIn
  • Conversation
  • Contact us
  • Feedback
  • Give to UOW

Northfields Ave Wollongong,  NSW 2522  Australia 
Phone: 1300 367 869 
International: +61 2 4221 3218 
Switchboard: +61 2 4221 3555

  • NUW Alliance: Smarter Solutions for NSW
  • University Global Partnership Network (UGPN)
  • Reconciliation Australia
  • AWEI LGBTQ inclusion awards logo

Aboriginal flag Torres Strait Islander flag

On the lands that we study, we walk, and we live, we acknowledge and respect the traditional custodians and cultural knowledge holders of these lands.

Copyright © 2023 University of Wollongong
CRICOS Provider No: 00102E | TEQSA Provider ID: PRV12062 | ABN: 61 060 567 686
Copyright & disclaimer | Privacy & cookie usage | Web Accessibility Statement

Close